FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

To be used in accordance with the following NICE TA(s) only:

Choice:

Amgevita (biosimilar brand) preferred brand for new patients.

Imraldi & Idacio for existing patients only

Humira for existing patients only (originator brand)

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved in accordance with the below NICE TAs (note: must be initiated by a NHSE designated specialist centre for TA392):

25mg, 50mg tablets

10mg/mL suspension. Restricted to paediatric patients or patients with swallowing difficulties.

Avoid concomitant use of azathioprine with allopurinol, unless supervised by an appropriate specialist.

NB: 75mg and 100mg tablets were rejected for use Feb 2024 due to safety concerns relating to dosing errors and disproportionate cost. Do not prescribe these strengths. 

Entry reviewed: August 2024

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

To be used in accordance with the following NICE TA(s) only:

RESTRICTED FOR ALL PRESCRIBING - Blueteq or high cost drug form required - see link from Formulary homepage,

To be used in accordance with the following NICE TA(s) only:-

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Restricted - for consultant dermatologist prescribing in line with NICE TA511.

FOR ALL PRESCRIBING - Blueteq or High Cost Drug Form required - see link from Formulary Homepage

RESTRICTED for Consultant Dermatologist prescribing in line with the following NICE TA(s):

See section 8.2.1

Entry reviewed May 2025

FOR ALL PRESCRIBING - Blueteq or high cost drug form required - see link from formulary homepage.

To be used in accordance with the following NICE TA(s):

Entry update: July 2023

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
Prescribing by specialist in accordance with NICE TA475.

Must not be prescribed on FP10 prescriptions

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved in accordance with NICE TA534 for the treatment of moderate to severe atopic eczema.

Preferred brand: Benepali

Enbrel (originator brand) for existing patients only

ALL prescribing of etanercept must be by brand name. 

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
  
 
Restricted - must be initiated by a Dermatology consultant only and must be prescribed by generic and brand name

Approved for use in accordance with the following NICE TA(s):

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
Prescribing by Dermatologist in accordance with NICE TA521.

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
To be prescribed by specialists in accordance with NICE TA442 and TA537.

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

To be used in accordance with the following NICE TA(s) only:

See section 10.1.3

Important: Metoject new pen device (available from March 2024): Manufacturer is updating the pen device to a button free autoinjector. Please ensure patients are aware and counselled appropriately on how to use the new device. Further details can be found here.

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

To be used in accordance with the following NICE TA(s) only:

Approved in accordance with NICE TA82 for the treatment of mild atopic eczema. For more information click the link below.

Approved for facial psoriasis where other topical agents have failed in line with BLMK ICB Management of plaque psoriasis in primary care pathway

Entry reviewed: May 2023

FOR ALL PRESCRIBING - Blueteq or High Cost Drug Form required - see link from Formulary Homepage.

Restricted to Specialist Prescribing in accordance with the following NICE TAs:

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

To be used in accordance with the following NICE TA(s) only:

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved for prescribing by Specialists in accordance with the following NICE TAs (note: must be initiated by a NHSE designated specialist centre for TA935):

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

To be used in accordance with the following NICE TA(s) only:

Entry reviewed: June 2025

0.03% & 0.1% Ointment

Approved in accordance with NICE TA82 for the treatment of mild atopic eczema.

Approved for facial psoriasis where other topical agents have failed in line with BLMK ICB Management of plaque psoriasis in primary care pathway

Entry reviewed: May 2023

FOR ALL PRESCRIBING - Blueteq or High Cost Drug Form Required - see link from Formulary Home Page. 

Approved in accordance NICE TA (s) below:-

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

To be used in accordance with the following NICE TA(s) only:

FOR ALL PRESCRIBING - Blueteq or High Cost Drug Form required - see link from Formulary Homepage.

To be used in accordance with the following NICE TA(s) only:

Pyzchiva® or Wezenla® (biosimilar brands) preferred for new patients.

Stelara® for existing patients only (originator brand)

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved in accordance with NICE TA180, TA455 and TA456.

Entry reviewed: October 2024

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Remicade (originator brand) for existing patients only

 
Approved in accordance with the below NICE TA(s):